78266-30-5Relevant academic research and scientific papers
1,4-Benzodiazepines as inhibitors of respiratory syncytial virus. The identification of a clinical candidate
Henderson, Elisa A.,Alber, Dagmar G.,Baxter, Robert C.,Bithell, Sian K.,Budworth, Joanna,Carter, Malcolm C.,Chubb, Ann,Cockerill, G. Stuart,Dowdell, Verity C. L.,Fraser, Ian J.,Harris, Robert A.,Keegan, Sally J.,Kelsey, Richard D.,Lumley, James A.,Stables, Jeremy N.,Weerasekera, Natasha,Wilson, Lara J.,Powell, Kenneth L.
, p. 1685 - 1692 (2007)
Respiratory syncytial virus (RSV) is the cause of one-fifth of all lower respiratory tract infections worldwide and is increasingly being recognized as representing a serious threat to patient groups with poorly functioning or immature immune systems. Rac
PHARMACEUTICAL COMPOSITION COMPRISING A BENZODIAZEPINE DERIVATIVE AND A INHIBITOR OF THE RSV FUSION PROTEIN
-
Page/Page column 35, (2008/06/13)
A pharmaceutical composition which comprises a pharmaceutically acceptable carrier or diluent and: (a) an inhibitor of the RSV fusion protein; and (b) a benzodiazepine derivative capable of inhibiting RSV replication is found to be highly active against R
